First-in-class cholesterol-lowering treatment NILEMDO ® ▼ (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI ® ▼ (bempedoic acid and ezetimibe) tablet approved in Switzerland
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics (NASDAQ: ESPR) announced today Swissmedic approval for NILEMDO®▼ (bempedoic acid) tablet and NUSTENDI®▼ (bempedoic acid and ezetimibe) tablet, offering new treatment options for people with high low-density lipoprotein cholesterol (LDL-C) in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005371/en/
Bempedoic acid is the first oral, once-daily treatment option approved in the last two decades for patients who have difficulty reaching their cholesterol-lowering goals. In a recent observational study, two-thirds of patients in Switzerland with very high cardiovascular risk did not achieve LDL-C target values set out by the European Society of Cardiology.3 Patients who do not reach their LDL-C lowering goals are at increased risk for heart attack and stroke.4 Diagnosis of high cholesterol has increased among older adults in Switzerland in the past 20 years.5
“Cardiovascular disease remains a leading cause of death in Switzerland. In 2017 it accounted for over 30% of deaths across the country, highlighting a critical need for new treatment options for the many people who are having difficulty reaching their LDL-C goals with existing lipid-lowering therapies,” said Dr. Lucas Schalch, Country Manager at Daiichi Sankyo Switzerland. “Today’s approval of NILEMDO® and NUSTENDI® is a pivotal milestone for patients in secondary prevention, offering them new, convenient treatment options and demonstrating another step forward in our commitment to reduce the risk of atherosclerotic cardiovascular disease.”
“Bempedoic acid is a first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver. This unique mechanism of action allows it to work alongside existing treatments,” said Ashley Hall, Chief Development Officer of Esperion. “Our focus is finding convenient, affordable ways for appropriate patients to manage LDL-C. That is why we also developed a single-tablet combination of bempedoic acid and ezetimibe, to help reduce pill burden.”
Bempedoic acid and its fixed combination drug product with ezetimibe were approved in the European Union and the United States earlier this year with different labels and indications.1,6,7,8 In Europe, the products are marketed as NILEMDO® and NUSTENDI®, and in the U.S. as NEXLETOL® and NEXLIZET® (respectively).1,6,7,8 The Esperion team discovered and developed bempedoic acid, drawing on its deep expertise in developing cholesterol-lowering medicines. With strong commercial capabilities, particularly in cardiovascular medicine, Daiichi Sankyo has licensed exclusive commercialization rights to bempedoic acid and the fixed combination drug product of bempedoic acid and ezetimibe in the European Economic Area, Turkey and Switzerland from Esperion. Marketing Authorization for both products in Switzerland will be transferred to Daiichi Sankyo.
Swissmedic approved bempedoic acid for the treatment of adults with clinically manifesting atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolaemia (HeFH) who need additional LDL-C lowering, as an adjunct to diet and in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies.9 The fixed combination drug product of bempedoic acid and ezetimibe is indicated as an adjunct to diet in adults with clinically manifesting ASCVD or HeFH for patients unable to reach LDL-C goals with the maximum tolerated dose of a statin combined with ezetimibe or bempedoic acid, or patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.10 Both approvals were supported by data from the CLEAR trial program, which included more than 3,600 high- and very-high-risk patients.9,10 The effect of bempedoic acid on cardiovascular morbidity and mortality is currently being investigated in 14,014 patients across 32 countries as part of the CLEAR Outcomes study.11
Bempedoic acid was generally well-tolerated in clinical studies. The most commonly reported adverse reactions with bempedoic acid during pivotal trials were hyperuricaemia, pain in extremity and anaemia. The majority of adverse reactions reported with bempedoic acid were mild to moderate in severity and balanced in occurrence with adverse events in patients receiving placebo.1,6-10
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Esperion’s commercialization plans for bempedoic acid tablet, its expectations for the market for medicines to lower LDL-C and the impact of bempedoic acid tablet in such market, including the commercial launch and the market adoption of bempedoic acid tablet in the United States and European Union. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion’s clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
▼ This medicinal product is subject to additional monitoring in the European Union
(1) European Medicines Agency. NILEMDO® Summary of Product Characteristics. 27 Nov 2020: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf.
(2) Pinkosky SL, et al. Liver- specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications. 2016; 7:13457. DOI:10.1038/ncomms13457.
(3) Rachamin Yael, et al. “Statin treatment and LDL target value achievement in Swiss general practice – a retrospective observational study,” 27 May 2020. Swiss Med Wkly. 2020;150:w20244: https://smw.ch/article/doi/smw.2020.20244.
(4) WHO. Cardiovascular diseases (CVDs) Factsheet. 2017. Available online at: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed December 2020.
(5) Swiss Federation Federal Statistical Office report, Gesundheitsstatistik 2019, 29 Oct 2019: https://www.bfs.admin.ch/bfsstatic/dam/assets/10227275/master.
(6) European Medicines Agency. NUSTENDI® Summary of Product Characteristics. 27 Nov 2020: https://www.ema.europa.eu/en/documents/product-information/nustendi-epar-product-information_en.pdf.
(7) U.S. Food and Drug Administration. NEXLETOL® Prescribing Information. 27 Nov 2020: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf.
(8) U.S. Food and Drug Administration. NEXLIZET® Prescribing Information. 27 Nov 2020: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211617s000lbl.pdf.
(9) Swissmedic. NILEMDO® (bempedoic acid) Product Information for Human Medicinal Products. December 2020.
(10) Swissmedic. NUSTENDI® (bempedoic acid and ezetimibe) Product Information for Human Medicinal Products. December 2020.
(11) Stephen J Nicholls et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. American Heart Journal (2020), https://doi.org/10.1016/j.ahj.2020.10.060.
Daiichi Sankyo Europe GmbH
Dr. Wolfgang Schiessl (Europe)
Director Product PR and Communications, Cardiovascular Europe
+49 151 1714 7317
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Viosys Begins Mass Production of 25Gbps VCSELs for 5G Communication Applications28.1.2021 09:40:00 CET | Press release
Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor provider, announced that for the first time in Korea, Seoul Viosys succeeded in developing vertical cavity surface emitting laser (VCSEL) technology, a near-field-only 25Gbps laser diode compatible with 5G wired networks for transmitting and receiving, and has started mass production to supply these products to three initial customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005444/en/ [Figure 1] Schematic diagram of 5G network application using Seoul Viosys’ VCSELs (Graphic: Business Wire) VCSEL is a laser diode technology that converts electrical signals into optical signals. It has recently attracted attention as a light-based communication technology that achieves ultra-high-speed data communication in 5G environments. This technology is necessary for AR/VR, 3D sensing and the camera-applied ToF (Time of Flight) for smartphones, and automotive L
REPLY: Spike Reply and Storm Reply Achieve AWS Security Competency Status28.1.2021 09:30:00 CET | Press release
Reply announced today that its companies Storm Reply and Spike Reply achieved Amazon Web Services (AWS) Security Competency status. This designation recognizes that the two companies of the Reply Group have demonstrated deep expertise that helps customers achieve their cloud security goals. Achieving the AWS Security Competency differentiates Storm Reply and Spike Reply as AWS Partner Network (APN) members that provide specialized consultancy services and integrated solutions designed to help enterprises adopt, develop and deploy complex security projects on AWS. To receive the designation, APN Partners must possess deep AWS expertise and deliver solutions seamlessly on AWS. Filippo Rizzante, CTO Reply, commented: “We are proud to be among the first APN partners to achieve AWS Security Competency status. This AWS competency status confirms the ability of our teams in helping companies achieve their security goals by combining our expertise with the range of powerful security tools that
Neustar highlights rise in ransom-related DDoS attacks and greater use of existing attack vectors28.1.2021 09:30:00 CET | Press release
Neustar, Inc., a global information services and technology company and leader in identity resolution, has today published its report entitled ‘Cyber Threats and Trends: Pandemic Style’, detailing the security risks faced by companies as the COVID-19 pandemic accelerated the digital revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005015/en/ Figure 1: Percentage change in number of attacks by size category, 2020 vs. 2019 (Graphic: Business Wire) Informed by data from Neustar’s Security Operations Center (SOC), the report reveals a 154 percent increase in the number of attacks between 2019 and 2020, with growth in ransom-related DDoS (RDDoS) attacks and a rise in use of existing attack vectors, including web applications. The report also provides key details around the amount, size, duration and intensity of DDoS attacks throughout 2020 to keep cyber security professionals informed. DDoS ransom attacks on the
STC calls on ADVA’s NFV suite for uCPE services28.1.2021 09:00:00 CET | Press release
ADVA (FSE: ADV) today announced that the Saudi Telecom Company (STC) is rolling out on-demand virtual services using ADVA’s Ensemble suite of network functions virtualization (NFV) technologies. The new universal CPE (uCPE) offering is built on the Dell EMC Networking Virtual Edge Platform (VEP) 1405 series running ADVA’s Ensemble Edge Cloud NFV suite. Enterprise customers of STC, the largest IT service provider in the Middle East, will be able to quickly and easily access virtual services, including routing, firewall, WAN optimization, IoT and voice applications. With the industry’s largest ecosystem of virtual network functions (VNFs) to choose from, managed service customers can automatically enable new applications and services without any financial risk. “Today’s enterprises need to be agile. They require the freedom to mix and match the latest cloud technologies to seize new revenue opportunities in an instant. That’s what our new uCPE service is all about. It eliminates vendor l
Temenos Transforms Corporate Banking with End-to-End, Cloud-Native Corporate Lending Platform28.1.2021 08:30:00 CET | Press release
Temenos (SIX: TEMN), the banking software company, today announced its next-generation end-to-end corporate lending platform, designed to help banks digitally transform their entire corporate banking business to reduce cost and drive operational efficiencies, improve customer experiences, and create offers for customers that are tailored to individual corporate needs. The microservices-based platform helps banks automate their heavily manual and complex processes and enables the bank’s corporate lending teams to access the right data at the right time to make faster and smarter decisions. Temenos’ corporate lending platform enables banks to evaluate loan applications more rapidly, structure complex corporate deals and handle negotiations in a transparent and efficient manner. It also allows banks to assess credit risk to maximize the performance of their product portfolio and capital, as well as help corporate customers access the right credit facilities for their needs. The digital co
Maistering B.V & Mesterbakeren AS Sign a 5-year Digital Transformation Deal28.1.2021 08:00:00 CET | Press release
Maistering,a global provider of an AI-infused business orchestration platform,today announced a strategic 5-year digital partnership with Mesterbakeren™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127006094/en/ Mesterbakeren™, headquartered in Oslo, Norway are the leading bakers offering the best in bread and bakery products to over 600 stores all over Norway. As part of this engagement, Maistering, through its artificial intelligence platform, Master Collections, will deliver a complete 360° business view through enhanced collaboration with Mesterbakeren’s factories, partners and retail stores. The new platform augments leadership and teams with digital grip through AI-infused engines for insight, collaboration, creation, execution and governance. Master Collections by Maistering is curated to enrich and speed up transformation initiatives. It allows leaders to plot and execute magical business journeys on the fly to
DNA Script Signs Innovation Development Contract With French Defence Innovation Agency to Enable On-Demand Diagnostics Against Emerging Biothreats28.1.2021 07:00:00 CET | Press release
DNA Script, a leading pioneer in enabling DNA synthesis on demand, today announced a partnership with the French Defence Innovation Agency, in liaison with the French Armament General Directorate (DGA), to develop a prototype for rapid mobile manufacturing of DNA primers and probes, key components of detection and diagnostic tests for pathogens. The joint project will employ DNA Script’s novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids. The prototypes to be developed by DNA Script will be evaluated by the DGA. As part of the agreement, DNA Script will receive $1.6 million in funding. In an emerging biothreat, like the ongoing COVID-19 pandemic, conventional sources of supply for key reagents (qPCR primers and probes in particular) become a limiting factor. Therefore, it is essential to enable an on-demand, agile source for custom reagent manufacturing. The DGA identified DNA Script’s SYNTAX™ platform, a benchtop instrument that synthesizes high-quality
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom